The most successful examples to date include the use of [11C]erlotinib, which was able to distinguish between sensitizing mutations of EGFR and wild type EGFR in non-small cell lung cancer patients, and [18F]afatinib showing a promising similar preclinical targeting profile in tumor bearing mice [10–14]. Here, EGFR is linked to non-small cell lung carcinoma.